News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Subscribe To Our Newsletter & Stay Updated
